Organon is a global pharmaceutical company spun out of Merck in 2021. Organon sells over 70 prescription drugs across three segments: women's health (~28% of revenue), established brands (~59%), and biosimilars (~11%), distributing to over 140 countries with roughly 74% of revenue generated outside the U.S. Women's health is Organon's strategic focus, anchored by Nexplanon — a long-acting contraceptive implant recently approved for five-year use — and fertility drugs like Follistim AQ used in IVF. Established brands is the largest segment and primary cash generator, consisting of mature, largely off-patent drugs across cardiovascular, respiratory, and dermatology categories; key products include Zetia, Singulair, Vtama (plaque psoriasis and atopic dermatitis), and Emgality (migraine prevention, licensed from Eli Lilly). This segment faces structural revenue decline from generic competition and mandatory government price cuts, particularly in China and Japan. Biosimilars is the fastest-growing segment, where Organon partners with Samsung Bioepis and Shanghai Henlius to commercialize immunology and oncology biosimilars, with Hadlima (a Humira biosimilar) as the primary growth driver. Organon sells through wholesalers, hospitals, and pharmacies, and generates roughly 60% gross margins. Near-term priorities center on deleveraging — net leverage stood at ~4.3x at end of 2025 — with management cutting the dividend and divesting assets to reduce debt. Organon's internal R&D pipeline is thin, and the company's growth strategy relies primarily on its existing portfolio and business development targeting late-stage or marketed assets.